Date and Time: 18th December 2013 (10.00 – 4.00pm)

Minutes: confirmed

Guideline Development Group Meeting 5: Coeliac disease

Place: Red Rooms, City Tower, Piccadilly Plaza, Manchester

Present: Damien Longson (Chair) (DL)
Mohamed Abuzak (MA)
Steph Briggs (SB)
Sorrell Burden (SB)
Martin Dadswell (MD)
Mike Forrest (MF)
Peter Gillett (PG)
Rajeev Gupta (RG)
Anne Holdoway (AH)
Norma McGough (NM)
Simon Murch (SM)
Gerry Robins (GR)
Rita Shergill-Bonner (RSB)

Apologies: Berne Ferry (BF)
David Sanders (DS)
Jeremy Woodward (JW)

In attendance:

<table>
<thead>
<tr>
<th>NICE Staff:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Emma Banks (EB)</td>
<td>Rachel Houten (RH)</td>
<td></td>
</tr>
<tr>
<td>Ben Doak (BD)</td>
<td>Gabriel Rogers (GR)</td>
<td></td>
</tr>
<tr>
<td>Sue Ellerby (SE)</td>
<td>Heather Stegenga (HS)</td>
<td></td>
</tr>
<tr>
<td>Michael Heath (MH)</td>
<td>Toni Tan (TT)</td>
<td></td>
</tr>
</tbody>
</table>

Notes

1. DL welcomed the group to the 5th meeting of this GDG. Apologies were received from BF, DS and JW. Minutes for the previous meeting were agreed.

2. All GDG members were asked to share any new conflicts of interest which have not been previously declared. No conflicts of interest were declared by the group or the NICE team.

3. HS presented the evidence for review question 1. The group acknowledged the difficulties posed by the different aspects of this review question, especially with
the overlaps between long-term consequences, signs and symptoms and coexisting conditions.

The evidence base for long-term consequences and first degree relatives was revisited. This followed a request from the group to include studies with serologically positive and biopsy-proven diagnosis of coeliac disease.

The group discussed the additional evidence presented for long-term consequences and first degree relatives and then the evidence for coexisting conditions.

The session closed with the group reviewing the draft evidence statements and confirming, with a few amendments, that they summarised the studies within the evidence review appropriately.

4. RH then explained to the group how the clinical evidence and group discussions of review question 1 will be utilised in the economic modelling in order to provide additional evidence for the review questions about active-case finding, diagnostic testing and monitoring strategies.

5. EB finished the day by providing an overview of the work the group had done to date and the schedule of work for 2014.

6. There were no further matters of business arising so DL drew to meeting to a close early, thanked all attendees for their input and confirmed the next meeting would be on the 30\textsuperscript{th} January 2014 (10 – 4.00pm) at NICE offices, Manchester.